发布时间: 2026 - 07 - 17
Recently, LightSaber, a single-use laser optical fiber catheter independently developed by Zhongke Rongguang, a subsidiary of Weiguang Medical, officially received approval for market launch from the National Medical Products Administration (NMPA) of China (Registration Certificate No.: 20263011418).The catheter is intended for use in combination with the previously approved FastErazer 355 nm cold laser atherectomy device (Registration Certificate No.: 20263011296) for the pretreatment of lower extremity atherosclerotic stenosis (including in-stent restenosis) and occlusive lesions, to facilit...
浏览次数:7
发布时间: 2026 - 07 - 16
China's life sciences industry has transformed into an innovation center of global significance, built upon accelerated regulatory pathways, strong policy support, and rapidly improving R&D efficiency across pharmaceuticals, medical devices, and biotechnology.Approximately 2,390 words | 5–6 min readFor a long time, China's innovative drug story was about the journey from "me-too" to "me-better." But halfway through 2026, the narrative has shifted—valuation is no longer driven by vision, but by hard metrics: pipeline data, deal values, and enrollment speed.KPMG&#...
浏览次数:4
发布时间: 2026 - 07 - 15
On July 15, the A-share market showed notable structural divergence, with the innovative drug sector leading gains across the board. Multiple sub-segments including CRO, weight-loss drugs, recombinant proteins, cellular immunotherapy, and generic innovation drugs all surged over 4%. On the same day, a piece of news about laboratory monkeys began circulating in the industry: the price of cynomolgus monkeys has exceeded 200,000 RMB per animal, and many monkey farms have told buyers that "this year's monkeys are already fully booked."These two seemingly unrelated pieces of informati...
浏览次数:5
发布时间: 2026 - 07 - 13
Recently, Jingze Bio's core pipeline project JZB32 (Recombinant Human Truncated Plasminogen Injection) was officially included in the National Science and Technology Major Project for Innovative Drug R&D, under the initiative "Innovative Drug R&D for Major Fundus Diseases Based on Cell Growth Factors."On July 5, 2026, the project kick-off meeting was grandly held at Wenzhou Medical University, bringing together top experts in ophthalmology and pharmaceutical sciences from across China to conduct in-depth discussions on collaborative R&D of original biologics for fundu...
浏览次数:4
115页次3/29首页PREV12345678910...NEXTlast page
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务